STCube Inc (052020) Fair Value & Analysis
Technology · KR · Market cap 498B KRW (≈ $349M) · ISIN KR7052020005
What is STCube Inc really worth?
Below-average quality, and trading another 846% above our fair value of 850.56 KRW.
Risks
Fair value as of: Aug 27, 2026
From 1 valuation models · updated 9 days ago
Fair value updated Aug 27, 2026, revised from 2,160 KRW to 850.56 KRW (−60.6%) since Aug 13, 2026. Share price +4.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (1,063 KRW). The favourable scenario is already priced in.
- Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (561.37 KRW to 1,063 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range 3,882 KRW – 23,439 KRW · fair‑value band 561.37 KRW – 1,063 KRW · the 8,050 KRW price screens above the 850.56 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
STCube Inc (052020) currently trades at 8,050 KRW, while our model-based Fair Value estimate is 850.56 KRW, implying the stock looks roughly 846.1% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Technology sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at 6.5B KRW. Revenue declined 31.3% year over year. Fundamentals as of Aug 27, 2026
Our scenario range runs from 561.37 KRW (bear case) to 1,063 KRW (bull case); at 8,050 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 64% below its 52-week high and 26% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at 64% fair-value upside, at −89%, 052020 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when 052020 reaches fair value
Put 052020 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea.
Full company description
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a technology designed to screen for antibodies that selectively mask specific sites of target proteins; and Glyco-Specific Antibody Characterization and Optimization Platform, a technology designed to optimize characteristics exerted by antibodies that mask specific sites of target proteins. The company's product pipeline consists of various anti-cancer drugs, including programmed death ligand 1, a type of protein, which is expressed in cancer cells and interferes with the natural tumor killing of immune cells; programmed death-1, a type of protein that is expressed in T cells; and cytotoxic T-lymphocyte associated protein 4, a protein that inhibits the activity of T-cells that can kill cancer cells. Its product pipeline also comprises lymphocyte-activation gene 3, a type of protein, which exists in the cell membrane of immune cells, such as T-cells and NK cells. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. STCube, Inc. was founded in 1989 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
STCube Inc reported revenue of 7.0B KRW in FY2025 versus 7.9B KRW in FY2021, a compound −3.1%/yr. Reported net income was −21.8B KRW in FY2025.
052020 screens 846% overvalued. Compare with VINATech Co →
Peer Group
Electronic Equipment & Parts · 19 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Electronic Equipment & Parts stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| VINATech Co 126340 | 76,700 KRW | 24,754 KRW | −68% |
| Partron Co 091700 | 5,500 KRW | 13,133 KRW | +139% |
| Amotech Co 052710 | 13,520 KRW | 14,277 KRW | +6% |
| KHVATEC Co 060720 | 11,770 KRW | 23,424 KRW | +99% |
| MNTech Co 095500 | 7,500 KRW | 8,280 KRW | +10% |
| Namuga Co 190510 | 14,530 KRW | 44,255 KRW | +205% |
| Powerlogics. Co 047310 | 3,055 KRW | 5,000 KRW | +64% |
| e-LITECOM CO., Ltd 041520 | 11,400 KRW | 11,520 KRW | +1% |
| Ajinextek Co 059120 | 7,440 KRW | 3,455 KRW | −54% |
| CoAsia Corporation 045970 | 3,140 KRW | 10,700 KRW | +241% |
Compare STCube Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Technology stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is STCube Inc (052020) overvalued or undervalued?
What is the fair value of 052020?
What is the quality score of 052020?
What is the revenue of STCube Inc (052020)?
What is the net profit margin of 052020?
Watch STCube Inc in the live analysis
One click puts STCube Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.